Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer
- 1 June 2002
- journal article
- Published by Elsevier in International Journal of Radiation Oncology*Biology*Physics
- Vol. 53 (2) , 297-303
- https://doi.org/10.1016/s0360-3016(02)02717-7
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Validating a treatment policy for PSA failures following 3D-conformal radiation therapyInternational Journal of Radiation Oncology*Biology*Physics, 2000
- Defining the appropriate radiation dose for pretreatment PSA ≤ 10 ng/mL prostate cancerInternational Journal of Radiation Oncology*Biology*Physics, 2000
- THE DURABILITY OF EXTERNAL BEAM RADIATION THERAPY FOR PROSTATE CANCER: CAN IT BE IDENTIFIED?Journal of Urology, 1999
- Outcome evaluation of the 1997 American Joint Committee on Cancer staging system for prostate carcinoma treated by radiation therapyCancer, 1999
- PROSTATE SPECIFIC ANTIGEN NADIR ACHIEVED BY MEN APPARENTLY CURED OF PROSTATE CANCER BY RADIOTHERAPYJournal of Urology, 1999
- PREDICTIVE VALUE OF PROSTATE SPECIFIC ANTIGEN NADIR AFTER SALVAGE CRYOTHERAPYJournal of Urology, 1998
- Evaluation of radiation effect, tumor differentiation, and prostate specific antigen staining in sequential prostate biopsies after external beam radiotherapy for patients with prostate carcinomaCancer, 1997
- Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancerCancer, 1993
- Prostatic-specific antigen doubling times in patients with prostate cancer: A potentially useful reflection of tumor doubling timeInternational Journal of Radiation Oncology*Biology*Physics, 1993
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958